Haemonetics Corporation

Equities

HAE

US4050241003

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
85.35 USD +1.50% Intraday chart for Haemonetics Corporation +6.93% -0.19%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Haemonetics to Acquire Attune Medical for $160 Million MT
Haemonetics Q3 Adjusted Earnings, Revenue Increase; Shares Rise MT
Transcript : Haemonetics Corporation, Q3 2024 Earnings Call, Feb 08, 2024
North American Morning Briefing : S&P 500 to Open -2- DJ
Haemonetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended December 30, 2023 CI
Haemonetics Corporation Updates Revenue Guidance for the Fiscal Year 2024 CI
Transcript : Haemonetics Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:45 AM
Haemonetics Completes $255 Million Acquisition of OpSens MT
OpSens Brief: NYSE's Haemonetics Completed Acquisition MT
Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS). CI
OpSens Receives Final Order For Its Acquisition By NYSE's Haemonetics MT
OpSens Brief: Says Received Final Order For Its Acquisition By NYSE's Haemonetics MT
Opsens Shareholders Approve Arrangement With Haemonetics MT
OpSens Brief: In connection with prior announced acquisition by Haemonetics Obtained Regulatory Clearance of Arrangement in the US and Canada; Regulatory Approvals Condition Satisfied MT
OpSens Fiscal Q4 Loss Narrows as Sales Rise 57% Ahead of Acquisition by Haemonetics MT
OpSens Brief: ISS Recommends Shareholders Vote For Opsens Inc. Plan of Arrangement with NYSE's Haemonetics MT
Barrington Cuts Price Target on Haemonetics to $105 From $114 on 'Macro Concerns', Keeps Outperform Rating MT
Transcript : Haemonetics Corporation, Q2 2024 Earnings Call, Nov 02, 2023
Haemonetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Haemonetics Corporation Revises Revenue Guidance for the Fiscal Year 2024 CI
Haemonetics Seeks M&A CI
Barrington Research's Initial Take on Haemonetics' Acquisition of OpSens MT
Needham on Opsens Being Acquired by Haemonetics MT
Toronto Stocks Advance; Opsens Soars on C$345 Million Buyout Deal DJ
OpSens Signed Definitive Agreement For Its Acquisition By NYSE's Haemonetics MT
Chart Haemonetics Corporation
More charts
Haemonetics Corporation is a global healthcare company. The Company provides a suite of medical products and solutions for customers to help them improve patient care and reduce the cost of healthcare. Its technology addresses three medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. Its segments include Plasma, Blood Center, and Hospital. Its Plasma segment offers automated plasma collection systems, donor management software, and supporting software solutions that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to collect and separate blood components for transfusions. Its Hospital segment provides patient care and has four product lines: hemostasis management, vascular closure, cell salvage, and transfusion management. Its portfolio also includes fiber optic sensor technology in the interventional cardiology market.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
85.35 USD
Average target price
107.2 USD
Spread / Average Target
+25.56%
Consensus
  1. Stock
  2. Equities
  3. Stock Haemonetics Corporation - Nyse
  4. News Haemonetics Corporation
  5. Insider Trends: Haemonetics Insider Disposition Interrupting 90-Day Buy Trend